Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.92
-0.3800-0.53%
Volume:3.24M
Turnover:229.27M
Market Cap:3.98B
PE:6.39
High:71.04
Open:70.96
Low:69.71
Close:71.30
52wk High:74.59
52wk Low:59.47
Shares:56.10M
Float Shares:56.10M
Volume Ratio:6.19
T/O Rate:5.78%
Dividend:0.81
Dividend Rate:1.14%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.42
PE(LYR):23.18

Loading ...

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Exchange-Traded Funds Rise as US Equities Advance After Midday

MT Newswires Live
·
Oct 03

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Oct 03

AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors

TIPRANKS
·
Oct 03

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Jobs Data

MT Newswires Live
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Oct 02

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

Reuters
·
Oct 02

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS
·
Oct 02

Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~

THOMSON REUTERS
·
Oct 02

J&J - 60% Scalp Psoriasis, 89% Genital Psoriasis Patients Achieve Complete Clearance at Week 112

THOMSON REUTERS
·
Oct 02

J&J - Safety Findings Through Week 112 Consistent with Icotyde Profile, no New Safety Signals

THOMSON REUTERS
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Dow Jones
·
Oct 02

Novartis Strikes up to $7.8 Billion mRNA Deal with China's Abogen

Reuters
·
Oct 02

Humana (HUM), Why Is It Back In The Spotlight?

Simply Wall St.
·
Oct 02

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Oct 02

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02